Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome

NCT07729592 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Dapagliflozin
DRUG: Donafenib
DRUG: Tislelizumab

Sponsor

Sun Yat-sen University